PPAPDC3 Antibody
Description
Target Protein: PPAPDC3
PPAPDC3, also known as NET39 or C9orf67, is a nuclear envelope transmembrane protein belonging to the PA-phosphatase-related phosphoesterase superfamily. Despite its classification, PPAPDC3 lacks detectable enzymatic activity and instead modulates cellular processes like myogenesis through MTOR signaling .
Table 1: Antibody Overview by Supplier
Key Findings:
-
Western Blot:
-
Immunofluorescence:
-
Functional Insights:
Table 2: Dilution Guidelines
| Application | Recommended Dilution | Sample Type |
|---|---|---|
| Western Blot | 1:500–1:1000 | Mouse skeletal muscle |
| Immunofluorescence | 20 μg/mL | Mouse heart tissue |
| Immunoprecipitation | 0.5–4.0 μg | Total protein lysate |
Research and Clinical Relevance
PPAPDC3 antibodies have been utilized in studies exploring:
Product Specs
Target Background
- NET39, a muscle-enriched nuclear envelope transmembrane protein, is involved in regulating the initiation of myogenic differentiation by affecting the mTOR-IGF-II pathway. PMID: 19704009
Q&A
What is PPAPDC3 and what is its biological significance?
PPAPDC3 (Phosphatidic acid phosphatase type 2 domain containing 3), also known as nuclear envelope transmembrane protein 39 (NET39), was initially discovered in an in silico screen for secreted or membrane proteins. It belongs to the PAP2 superfamily of phosphatases and haloperoxidases. PPAPDC3 acts as a negative regulator of myoblast differentiation by diminishing the activity of the mammalian target of rapamycin (mTOR). It is highly expressed in cardiac and skeletal muscle tissues and becomes strongly upregulated during cultured myoblast differentiation . Despite being in the phosphatase family, it reportedly has no detectable enzymatic activity, suggesting it may function through protein-protein interactions rather than direct enzymatic activity .
What molecular weight should I expect when detecting PPAPDC3?
PPAPDC3 presents an interesting case of discrepancy between calculated and observed molecular weights:
| Parameter | Molecular Weight | Source |
|---|---|---|
| Calculated molecular weight | 29 kDa (271 amino acids) | |
| Observed molecular weight (WB) | 68 kDa |
This discrepancy should be considered when validating antibody specificity. The difference may be attributed to post-translational modifications, protein-protein interactions, or anomalous migration in SDS-PAGE. When using Western blot, researchers should be prepared to observe bands at approximately 68 kDa rather than the calculated 29 kDa .
What tissue samples are optimal for PPAPDC3 antibody validation?
Based on expression profiles, the following tissues provide optimal positive controls:
| Tissue Type | Expression Level | Application |
|---|---|---|
| Cardiac muscle | High | WB, IF, IHC |
| Skeletal muscle | High | WB, IF, IHC |
| Differentiating myoblasts | Strongly upregulated | Cell-based assays |
Mouse heart tissue lysate (15 μg) has been successfully used in Western blot applications at antibody concentrations of 1-2 μg/mL . For immunofluorescence, mouse heart tissue with antibody concentration of 20 μg/mL has yielded positive results .
How does immunogen design impact PPAPDC3 antibody performance?
The design of immunogens significantly affects both antibody success rate and specificity:
When selecting PPAPDC3 antibodies, researchers should consider this trade-off between production success and specificity. Many commercial PPAPDC3 antibodies are raised against synthetic peptides from the amino terminus region, which appears to provide good specificity for this protein .
What validation strategies ensure reliable PPAPDC3 antibody performance?
A comprehensive validation approach should include multiple complementary methods:
According to Human Protein Atlas standards, antibodies are categorized based on validation reliability. For PPAPDC3, immunofluorescence (ICC) applications have shown the highest success rate (95.06%) compared to immunohistochemistry (IHC, 74.8%) and Western blot (WB, 52%) .
How should I optimize Western blot protocols for PPAPDC3 detection?
Successful Western blot detection of PPAPDC3 requires specific optimization:
To reduce non-specific binding, increase washing steps and consider using a gradient gel (4-15%) to better resolve proteins around the observed molecular weight of 68 kDa. The discrepancy between observed and calculated molecular weights makes additional validation controls particularly important for PPAPDC3 .
What are key considerations for immunofluorescence with PPAPDC3 antibodies?
For optimal immunofluorescence results with PPAPDC3 antibodies:
Given PPAPDC3's alternative name as nuclear envelope transmembrane protein 39 (NET39), expected localization should include the nuclear envelope, particularly in muscle cells where expression is highest .
How can I use PPAPDC3 antibodies in myoblast differentiation studies?
PPAPDC3's role in myoblast differentiation makes it valuable for muscle development research:
Since overexpression of PPAPDC3 in myoblasts represses myogenesis while knockdown promotes differentiation, antibodies can be valuable tools to confirm protein levels in these experimental manipulations .
How can I address non-specific binding with PPAPDC3 antibodies?
Non-specific binding can be minimized through several approaches:
| Challenge | Solution Strategy |
|---|---|
| Multiple bands | Increase washing stringency; try different blocking agents (BSA vs. milk) |
| High background | Reduce antibody concentration; increase blocking time/concentration |
| Cross-reactivity | Pre-absorb antibody with non-expressing tissues; use antibodies raised against unique epitopes |
| Inconsistent results | Compare multiple antibodies targeting different epitopes of PPAPDC3 |
Given the discrepancy between calculated and observed molecular weights for PPAPDC3, additional validation steps are particularly important to confirm band specificity .
What controls are essential for definitive PPAPDC3 antibody validation?
For rigorous validation, include these essential controls:
Commercial recombinant protein control fragments, such as Human PPAPDC3 (aa 170-202) Control Fragment, can be valuable for blocking experiments to confirm antibody specificity .
How should I interpret contradictory results when using PPAPDC3 antibodies?
When faced with contradictory results:
The observed molecular weight discrepancy (68 kDa vs. calculated 29 kDa) is consistently reported across multiple sources and may reflect true biological features of PPAPDC3 rather than antibody artifacts .
How can PPAPDC3 antibodies contribute to muscle development and disease research?
PPAPDC3's role in myoblast differentiation suggests broader applications:
| Research Area | Antibody Application |
|---|---|
| Muscle development | Track PPAPDC3 expression during developmental stages |
| Muscle regeneration | Examine expression changes following injury |
| Muscular dystrophies | Compare PPAPDC3 levels in normal vs. dystrophic muscle |
| mTOR signaling | Investigate PPAPDC3's interaction with mTOR pathway components |
Given that PPAPDC3 negatively regulates myoblast differentiation through effects on mTOR signaling, antibodies against this protein may provide insights into regulatory mechanisms of muscle development and potential therapeutic targets for muscle diseases .
What technological advances are improving PPAPDC3 antibody development?
Recent methodological improvements in antibody development include:
The Human Protein Atlas approach of systematically evaluating immunogen properties helps identify key factors influencing antibody suitability, which can guide selection of optimal PPAPDC3 antibodies for specific applications .
